CVS Health Corporation
CVS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.28 | 0.13 | -0.63 | 1.79 |
| FCF Yield | 11.19% | 10.25% | 11.00% | 11.57% |
| EV / EBITDA | 9.56 | 9.49 | 14.58 | 11.56 |
| Quality | ||||
| ROIC | 3.61% | 5.87% | 3.63% | 5.90% |
| Gross Margin | 13.79% | 15.21% | 16.90% | 17.84% |
| Cash Conversion Ratio | 1.99 | 1.60 | 3.74 | 2.29 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.95% | 6.99% | 6.27% | 4.39% |
| Free Cash Flow Growth | -39.14% | -22.71% | -14.58% | 17.25% |
| Safety | ||||
| Net Debt / EBITDA | 5.43 | 3.91 | 4.68 | 3.80 |
| Interest Coverage | 2.88 | 5.17 | 3.48 | 5.32 |
| Efficiency | ||||
| Inventory Turnover | 17.75 | 16.83 | 14.04 | 13.51 |
| Cash Conversion Cycle | 38.22 | 39.70 | 36.67 | 38.46 |